n South African Gastroenterology Review - Revellex® (infliximab) now indicated for ulcerative colitis and paediatric crohn's disease : product news

Volume 7, Issue 2
  • ISSN : 1812-1659



Revellex® (infliximab) is a monoclonal antibody that specifically targets tumor necrosis factor-alpha (TNF-α), which has been shown to play a role in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, paediatric Crohn's disease, psoriatic arthritis, and plaque psoriasis. Revellex is the global market leader among anti-TNF-α therapies and was the first agent approved for the treatment of both ulcerative colitis and Crohn's disease.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error